Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:

NCT ID: NCT06193980 Recruiting - Sepsis Clinical Trials

Exercise Testing in ICU Survivors to Evaluate ICU-acquired Weakness

Start date: December 15, 2023
Phase:
Study type: Observational

This study aims to investigate how sepsis and shock can impair microcirculation in intensive care unit (ICU) patients, which can lead to long-lasting muscle weakness/dysfunction or ICU-Acquired Weakness (ICU-AW) and exercise limitations.

NCT ID: NCT06193109 Completed - Clinical trials for Sepsis and Septic Shock

The Prognostic Impact of Right Ventricular Systolic Dysfunction on the Survival of Patients With Sepsis and Septic Shock

Start date: October 1, 2022
Phase:
Study type: Observational

This study sought to evaluate the association of right ventricular systolic dysfunction and 28-day in-hospital mortality in patients with sepsis and septic shock. Prospective cohort study of adult patients admitted at Burapha university hospital from October 1, 2022 through June 30, 2023 for sepsis and septic shock, who had an echocardiogram within 72 hours after admission for evaluating right ventricular systolic function. Right ventricular systolic dysfunction was defned by the American Society of Echocardiography criteria. Outcomes included 28-day in-hospital mortality, maximal blood lactate, length of intensive care unit(ICU) stay and duration of mechanical ventilation.

NCT ID: NCT06191523 Completed - Sepsis Newborn Clinical Trials

The Effect of Melatonin as an Adjuvant Therapy for Preterm Neonates With Sepsis

Start date: April 27, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assess the effect of melatonin on MDA serum, IL-6, IL-8 levels, ANC, and sepsis score in preterm neonates with sepsis. The main question aim to answer : • Does melatonin affect MDA serum, IL-6, IL-8 levels, ANC, and sepsis score in preterm neonates with sepsis? The participants in the treatment group will receive a single dose of oral melatonin 20 mg, meanwhile those the control group will receive placebo. The researchers will compare MDA serum, IL-6, IL-8 levels, ANC, and sepsis score before and after receiving melatonin, whether there are decreases of MDA serum, IL-6, IL-8 levels, ANC and increase of sepsis score

NCT ID: NCT06187168 Recruiting - Sepsis Clinical Trials

Risk Factors of Post-ERCP Sepsis

Start date: December 23, 2023
Phase:
Study type: Observational

For the treatment of numerous biliary and pancreatic problems, the procedure known as endoscopic retrograde cholangiopancreatography (ERCP) is regarded as a crucial therapeutic intervention. However, ERCP is known to be connected to a variety of issues, including post-ERCP sepsis. This study's goal is to investigate the relationship between unexplained hypotension during or just after surgery and the emergence of sepsis after ERCP.

NCT ID: NCT06184659 Not yet recruiting - Sepsis Clinical Trials

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

EMPRESS
Start date: August 1, 2024
Phase: Phase 4
Study type: Interventional

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

NCT ID: NCT06181604 Active, not recruiting - Sepsis Clinical Trials

Multicenter Symphony IL-6 Monitoring Sepsis ICU Study

SYMON
Start date: January 12, 2024
Phase:
Study type: Observational

The primary objective of this study is to establish an IL-6 concentration cutoff and optimal time point(s) for using Symphony IL-6 that predict 28-day mortality in patients who are admitted or are intended to be admitted to the intensive care unit (ICU) diagnosed with sepsis or septic shock.

NCT ID: NCT06181422 Recruiting - Sepsis Clinical Trials

Metformin and Lactoferrin in Sepsis in Icu

Start date: April 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Sepsis is a life-threatening organ dysfunction triggered by an unregulated response of a host to infection. Sepsis is a reason for substantial mortality and morbidity among intensive care unit (ICU) patients. 1 Therefore, the aim of our study is to compare the safety and efficacy of metformin and lactoferrin in ICU patients with sepsis.

NCT ID: NCT06178822 Recruiting - Sepsis Clinical Trials

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

BIOSEP
Start date: October 25, 2022
Phase:
Study type: Observational [Patient Registry]

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

NCT ID: NCT06174649 Recruiting - Clinical trials for Bloodstream Infection

Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial

FAST
Start date: December 22, 2023
Phase: N/A
Study type: Interventional

This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive blood cultures characterized using standard of care (SOC) antimicrobial susceptibility testing (AST) vs. a rapid AST method known as Revealâ„¢ in addition to SOC AST. The purpose of the FAST trial is to evaluate whether use of a rapid phenotypic AST improves clinical outcomes compared to use of SOC AST methods in clinical settings with high resistance rates.

NCT ID: NCT06167083 Active, not recruiting - Clinical trials for Carbapenem Resistant Bacterial Infection

Machine Learning in the ICU: Predicting Mortality in Bloodstream Infections (ICU:Intensive Care Unit)

ICU
Start date: April 12, 2024
Phase:
Study type: Observational

Using our own patient data, our study aimed to predict mortality that can develop in Carbapenem-resistant Gram-negative bacilli bloodstream infections with a machine learning-based model. In the intensive care unit, patients with bloodstream infections, both with and without mortality, will be examined retrospectively in two subgroups for comparison.